Retina Society 2026: Could statins reduce PVR risk after RD repair?

Proliferative vitreoretinopathy (PVR) remains a complication without an FDA-approved treatment or prevention strategy, affecting approximately 10% of all retinal detachment repairs. That was the starting point for Christina Y. Weng, MD, MBA, FASRS, Professor and Alice R. McPherson Retina Research Foundation Chair in Ophthalmology and Fellowship Program Director, Vitreoretinal Diseases and Surgery at Baylor College of Medicine, Houston, Texas, who presented findings from a multicenter database study at the 59th Annual Scientific Meeting of The Retina Society, September 23-26, 2026, in Los Angeles, California.

Although methotrexate—injected intravitreally—has shown promising effects in the prevention of PVR, particularly after an initial PVR presentation and in subsequent surgeries, there are challenges with that medication, Weng noted. The typical treatment series in the GUARD study (NCT04136366) involved 13 injections—a regimen that patients find difficult to adhere to, and one that requires access to a compounding pharmacy given that the medication is not yet FDA approved. Patients do not like injections in the eye in general, she noted, adding that there is “lots of room for improvement here.”

Against that backdrop, Weng and her team turned their attention to statins. “I want to give a shout-out to all of my co-authors, especially to Jawad Muayad, Asad Loya, and Darius D. Bordbar, who spearheaded this work,” she said. As the most commonly prescribed medications for high cholesterol, statins also possess anti-inflammatory and anti-fibrotic properties that are directly relevant to the pathophysiology of PVR. The study also sought to determine whether a dose-dependent or drug-specific effect existed.

Study design and findings

Using the TriNetX federated database, the team identified patients with dyslipidemia who underwent primary retinal detachment repair and divided them into two groups—those on statins at the time of repair and those with no history of statin or antilipemic use. After propensity score matching, two well-balanced cohorts of nearly 5,000 patients each were established. The analysis found that statin use reduced the risk of PVR by 25% and also reduced the risk of needing reoperation.

On the question of mechanism, Weng pointed to prior research showing that statins reduce contraction of hyalocyte-containing collagen cells, both in vivo and in vitro, and inhibit expression of IL-6, IL-8, and MCP-1—key PVR mediators in retinal pigment epithelial cells. The study also appeared to uncover a dose-dependent effect, with high-intensity statin use yielding the most pronounced protection. Exploratory analyses further suggested that molecular lipophilicity—which affects vitreous penetration—mattered, and that more lipophilic statins such as atorvastatin and simvastatin were linked with greater PVR risk reduction.

Clinical implications and next steps

Weng was careful to note the limitations of database studies, emphasizing that prospective validation is needed before statins could be administered or recommended to patients for this PVR indication. She cited several recent database and even smaller clinical studies that have aligned with their findings, including a recent pilot randomized study that found PVR incidence was lowered from 22% to 3.8%. “I hope we can build on this momentum,” she said.

Looking ahead, she identified several key questions that prospective study would need to address—whether statins would be given to every patient or only high-risk ones, the appropriate dose and duration of treatment, and whether statins would function as a prophylactic monotherapy or an adjunctive treatment. She also pointed to the broader trend toward oral and systemic medications for ocular conditions as an area of growing interest, noting that patients respond positively to the concept of self-administered medications that reduce the frequency of office visits. “The great news about statins especially is that we know that they are very well tolerated,” she said. “They have an excellent safety track record because they are one of the oldest medications that we’ve used for a different indication, but if we can apply it to a different disease, especially one that robs so many patients of their vision every single year, that’d be really promising.”